Needham & Company Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR); Adjusted Estimates Ahead of Q4 Results

Needham & Company reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $19.00.

Analyst, Alan Carr, said, "Optimer is scheduled to release 2011 earnings tomorrow after market close (3/7/12). The company preannounced top-line financial results early in January 2012, with gross 4Q11 Dificid sales of approximately $12.2M and 4675 Dificid shipments to wholesalers. We now estimate $10.9M in net sales (was $14.0M). Our new 4Q11 EPS estimate is $0.57 (was $(0.51)), which also reflects recognition of a milestone payment from collaborator Astellas. Based on IMS data to date, we are not making any material changes to our 2012 Dificid sales estimates."

Needham lowers FY12 EPS estimate from (0.10) to (1.25) and cuts FY revs from $158.7 mln to $101.9 mln.

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $12.72 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• HomeTrust to acquire Blue Ridge Bankshares in $448M all-stock deal